IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NOS.: See attached Schedule A

ASSIGNEE: TargeGen, Inc.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the patent applications identified in the attached Schedule A, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 051414** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent applications to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent applications is **TargeGen**, **Inc.** by virtue of the chain of title from the inventors of the above-identified patent applications to the current assignee.

Respectfully submitted,

Dated: September 6, 2007

Peter G. Ulrich, President and CEO

TargeGen, Inc.

9380 Judicial Drive

San Diego, California 92121

United States of America

Schedule A

Application	Filing	Title	Attorney Docket	Reel and
No./Patent	Date		No./Former	Frame
No.			Attorney Docket No.	Number
7,208,493	10/02/03	Vasculostatic Agents and Methods	TRG-	014666/0766
		of Use Thereof	111/TARG-	
			1110-3	
11/653,190	01/11/07	Vasculostatic Agents and Methods	TRG-	014666/0766
		of Use Thereof	111C1/TARG-	
,			1110-5	24.522.42.24
11/105,845	04/13/05	Vasculostatic Agents and Methods	TRG-	016023/0024
		of Use Thereof	111CP/TARG-	
			1110-4	100506/0500
60/415,981	10/03/02	SRC Inhibitors and Methods for	TRG-	103586/0793
		Use Thereof	111P1/TARG-	
	0.1 (1.1 (0.0		1110	012776/0404
60/440,234	01/14/03	SRC Inhibitors and Methods for	TRG-	013776/0484
		Use Thereof	111P2/TARG-	,
	0.6/4.5/0.0	**	1110-1	01.4450/0407
60/479,295	06/17/03	Vascular Permeability Inhibitors	TRG-	014458/0427
		and Methods for Use Thereof	111P3/TARG- 1110-2	
11/102 405	04/07/05	Benzotriazine Inhibitors of	TRG-	016424/0283
11/102,405	04/07/05	Kinases	116/TARG-	010424/0263
		Killases	1160-2	
60/561,237	04/08/04	Benzotriazine Inhibitors of	TRG-	016467/0841
00/301,237	04/08/04	Kinases	116P1/TARG-	01040770041
		Killases	1160	
60/643,439	01/12/05	Benzotriazine Inhibitors of	TRG-	016467-0864
00/015,155	01/12/05	Kinases	116P2/TARG-	
			1160-1	
11/212,064	08/24/05	Heterocyclic Compounds and	TRG-	019411/0368
		Methods of Use	121/TARG-	
			1210-2	
60/604,298	08/25/04	Heterocyclic Compounds and	TRG-	01941/0301
		Methods of Use	121P1/TARG-	
			1210	
60/696,168	07/01/05	Heterocyclic Compounds and	TRG-	019411/0334
		Methods of Use	121P2/TARG-	
			1210-1	
11/377,234	03/15/06	Pyrimidine Inhibitors of Kinases	TRG-123-	018049/0517
			1/TARG-1230-1	

No. Patent No. N	Application	Filing	Title	Attorney Docket	Reel and
11/449,219 06/07/06 Methods and Compositions for the Treatment of Ocular Disorders 124/TARG-1240-3 1250-3 12	No./Patent	Date		No./Former	Frame
11/449,219	No.			Attorney Docket	Number
Treatment of Ocular Disorders 124/TARG- 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-3 1240-1 1240 1240-1 1240 1240 1240-1 1250-2 1250-2 11/796,717 04/26/07 Bi-Aryl Meta-Pyrimidine TRG- 1250-2 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-1 1250-1 1250-1 1250-1 1250-1 1250-1 11/591,076 10/31/06 Bi-Aryl Meta-Pyrimidine TRG- 1250-1 1250-1 11/591,252 10/31/06 Inhibitors Targeting Resistant TRG- 1260A-1 1260A-1 1260A-1 1260A-1 1260A-1 1260A-1 1260A-2 1260-2 127/TARG- 1260-2 127/TARG- 1260-2 127/TARG- 127/TA				No.	
1240-3	11/449,219	06/07/06	Methods and Compositions for the	TRG-	018610/0877
Methods and Compositions for the Delivery of Lipophilic Drugs			Treatment of Ocular Disorders	124/TARG-	
Delivery of Lipophilic Drugs 124P1/TARG-1240				1240-3	
Delivery of Lipophilic Drugs 124P1/TARG-1240	60/689,111	06/08/05	Methods and Compositions for the	TRG-	016467/0847
Methods and Compositions for the Delivery of Lipophilic Drugs				124P1/TARG-	
Delivery of Lipophilic Drugs 124P2/TARG-1240-1				1240	
1240-1	60/763,537	01/30/06	Methods and Compositions for the	TRG-	018610/0877
11/588,638 10/26/06 Bi-Aryl Meta-Pyrimidine 125/TARG- 1250-2 1250-2 11/796,717 04/26/07 Bi-Aryl Meta-Pyrimidine TRG- 125CP/TARG- 1250-3 1250-3 1250-3 11/01/05 Bi-Aryl Meta-Pyrimidine TRG- 12591/TARG- 12591/TARG- 1250 12591/TARG- 1250 1250-3 1260/3 12			Delivery of Lipophilic Drugs	124P2/TARG-	
Inhibitors of Kinases 125/TARG- 1250-2 11/796,717 04/26/07 Bi-Aryl Meta-Pyrimidine TRG- 125CP/TARG- 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-1 1250-1 1250-1 11/591,076 10/31/06 Inhibitors of Kinases 125P1/TARG- 1250-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant Kinase Mutations TRG- 1260A-1 1260A-1 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine TRG- 127/TARG-				1240-1	
1250-2 11/796,717 04/26/07 Bi-Aryl Meta-Pyrimidine TRG- 125CP/TARG- 125D-3 12	11/588,638	10/26/06	Bi-Aryl Meta-Pyrimidine	TRG-	018791/0911
11/796,717 04/26/07 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases 125CP/TARG-1250-3 1250-3 1250-3 11/01/05 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases 125P1/TARG-1250 125P1/TARG-1250 125P1/TARG-1250 125P1/TARG-1250 125P2/TARG-1250-1 11/591,076 10/31/06 Inhibitors of Kinases 125P2/TARG-1250-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant TRG-1260A-1 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors and Methods of Use Thereof 128/TARG-1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG-128			Inhibitors of Kinases	125/TARG-	
Inhibitors of Kinases 125CP/TARG-1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-3 1250-1 1250 1250 1250 1250 1250 1250-1 11/591,076 10/31/06 Inhibitors Targeting Resistant Kinase 126A/TARG-1260A-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant Kinase Mutations 126B/TARG-1260-2 1260-2 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors 127/TARG-1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG-				1250-2	
1250-3 1250-3 160/732,629 11/01/05 Bi-Aryl Meta-Pyrimidine TRG- 125P1/TARG- 125D 125D-1 126DA-1 126DA-1 126DA-1 126DA-1 126DA-1 126DA-1 126DA-1 126D-2 126D-2 127/TARG- 126D-2 127/TARG- 127/	11/796,717	04/26/07	Bi-Aryl Meta-Pyrimidine	TRG-	019600/0122
11/01/05 Bi-Aryl Meta-Pyrimidine TRG- 125P1/TARG- 1250			Inhibitors of Kinases	125CP/TARG-	
Inhibitors of Kinases 125P1/TARG-1250 1250 1250 1250 1250 1250 1250 1250 1250 1250 1250 1250-1 11/591,076 10/31/06 Inhibitors Targeting Resistant Kinase 126A/TARG-1260A-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant Kinase Mutations 126B/TARG-1260-2 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors 127/TARG-127/TARG-1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG-128				1250-3	
1250	60/732,629	11/01/05	Bi-Aryl Meta-Pyrimidine	TRG-	018916/0540
11/591,076 10/31/06 Bi-Aryl Meta-Pyrimidine 125P2/TARG-1250-1 11/591,076 10/31/06 Inhibitors Targeting Resistant TRG-1260A-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting TRG-1260A-1 11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant Kinase Mutations 126B/TARG-1260-2 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine TRG-127/TARG-1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG-12			Inhibitors of Kinases	125P1/TARG-	
Inhibitors of Kinases 125P2/TARG-1250-1				1250	•
Inhibitors of Kinases 125P2/TARG-1250-1	60/838,003	08/15/06	Bi-Aryl Meta-Pyrimidine	TRG-	018782/0239
11/591,076				125P2/TARG-	
Kinase				1250-1	
Kinase	11/591,076	10/31/06	Inhibitors Targeting Resistant	TRG-	018964/0673
11/591,252 10/31/06 Thiazole Inhibitors Targeting Resistant Kinase Mutations TRG-126B/TARG-1260-2 018964/0732 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors TRG-127/TARG-1270-1 019774/0567 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof TRG-128/TARG-128/				126A/TARG-	
Resistant Kinase Mutations 126B/TARG- 1260-2 11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine TRG- Inhibitors 127/TARG- 1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG-				1260A-1	
11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors TRG-127/TARG-1270-1 019774/0567 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof TRG-128/TARG-1	11/591,252	10/31/06	Thiazole Inhibitors Targeting	TRG-	018964/0732
11/772,572 07/02/07 2-Amino-5-Substituted Pyrimidine Inhibitors TRG-127/TARG-1270-1 019774/0567 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof TRG-128/TARG-1			Resistant Kinase Mutations	126B/TARG-	
Inhibitors 127/TARG- 1270-1 11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG- Use Thereof 128/TARG-				1260-2	
11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof TRG-1019600/0230	11/772,572	07/02/07	2-Amino-5-Substituted Pyrimidine	TRG-	019774/0567
11/789,832 04/25/07 Kinase Inhibitors and Methods of Use Thereof 128/TARG- 019600/0230			Inhibitors	127/TARG-	
Use Thereof 128/TARG-				1270-1	
	11/789,832	04/25/07	Kinase Inhibitors and Methods of	TRG-	019600/0230
1280-1			Use Thereof	128/TARG-	
				1280-1	